In-body manufacturing promises a faster, cheaper and simpler alternative to CAR-T cell therapy — if the field can deliver clinical readouts that prove long-term safety and efficacy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A.M. consults for Haystack Science; no company mentioned in this story is a client.
Rights and permissions
About this article
Cite this article
Marshall, A. In vivo CAR-Ts captivate big pharma. Nat Biotechnol 43, 1893–1896 (2025). https://doi.org/10.1038/s41587-025-02955-8
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02955-8
